Trisaq

Founded in 2011, Trisaq is a life sciences company focused on developing drugs to treat chronic kidney disease. The company's therapeutic approach aims to reverse the disease's progression by eliminating or modulating specific molecular targets. These targets are responsible for the destruction of podocytes, which are crucial cells in the kidney's filtration system, and the overall deterioration of kidney function.

The firm's stated goal is to provide healthcare providers with treatments that can potentially cure chronic kidney diseases. While based in the United States, with a corporate office listed in Miami, Florida, and an initial location in Las Vegas, Nevada, the company was noted as being out of business as of September 2020. Prior to this, it was identified as being in the Later Stage VC (Series A) phase, although it is also listed as an unfunded company.

Keywords: chronic kidney disease, therapeutics, renal disorders, drug development, podocytes, kidney function, life sciences, biopharmaceutical, molecular targets, kidney disease treatment, nephrology, healthcare, medical research, clinical development, pharmaceutical